Initial trial of slow-release testosterone microspheres in hypogonadal men*
|
|
- Lesley Pearson
- 5 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY Copyright c 1988 The American Fertility Society Printed in U.S.A. Initial trial of slow-release testosterone microspheres in hypogonadal men* Allen S. Burris, M.D. t Larry L. Ewing, Ph.D.* RichardJ. Sherins, M.D.t National Institute of Child Health and Human Development, Bethesda, and The Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland The duration of hormone release from testosterone-loaded poly(dl-lactide-co-glycolide) microspheres was assessed in eight hypogonadal men. Eight weeks before receiving testosterone (T) microspheres, patients were withdrawn from their prior androgen therapy in order to minimize the contribution of that therapy to hormone levels measured following microsphere injection. Blood was obtained for hormone measurements immediately before and weekly for 14 weeks after the administration of the T microspheres. A biphasic release of hormone was observed; a significant increase in total T and free T concentration (compared to preinjection values) was observed during week 1 (P < 0.01) and between weeks 6 and 11 after injection (P < 0.05). A similar pattern was detected in estradiol and dihydrotestosterone concentrations, whereas T -binding globulin levels showed a small, reciprocal fall after the injection of microspheres (P = not significant [NS]). After receiving the T microspheres, seven of eight hypogonadal men reported the return of normal sexual function; the eighth patient withdrew from the study after 5 weeks. It was concluded that T microspheres are a promising new method of androgen replacement therapy for hypogonadal men. Fertil Steril , 1988 The intramuscular administration of a long-acting testosterone (T) ester such as T enanthate or T cypionate is presently the most effective method for androgen replacement in men with hypogonadism.1 2 However, the pharmacokinetics of the T esters mandate a 1- or 2-week dosing interval in order to sustain the blood concentration of T within a therapeutic range. 3 4 The microencapsulation of a hormone allows for the effective, long-term release of the hormone in vivo. 5 By dispersing the hormon e in a biodegradable polymer matrix, sustained blood levels may be achieved after injection. 6 9 After preliminary studies conducted in primates, 10 we tested T-loaded poly(dl-lactide-co-glycolide) microspheres that were designed to release T over a period of 12 weeks after intramuscular injection. We administered the T microspheres to eight hypogonadal men in order to determine the clinical efficacy of the preparation and duration of T release. Received February 2, 1988; accepted May 10, *Supported in part by the National Institutes of Health grant HD and the Population Center grant HP t Developmental Endocrinology Branch, National Institute of Child Health and Human Development. *Division of Reproductive Biology, The Johns Hopkins School of Hygiene and Public Health. Reprint requests: Richard J. Sherins, M.D., National Institutes of Health, Building 10, Room 10N262, Bethesda, Maryland Subject Selection MATERIALS AND METHODS Eight hypogonadal men between 22 and 57 years of age (41.1 ± 4.2, mean ± standard error of the mean [SEM]) were enrolled in the study (Table 1). Four patients had a diagnosis of isolated hypogonadotropic hypogonadism (IHH), three patients Burris et al. Testosterone microspheres 493
2 Table 1 Pretreatment Clinical Characteristics of Hypogonadal Men Who Received Testosterone Microspheres Age Patient (yr) Primary diagnosis Other diagnoses Treatment history Serum T" (ng/dl) IHHb NIDDM Testosterone enanthate IHH Bilateral cryptorchidism Testosterone enanthate IHH Testosterone enanthate IHH Bilateral cryptorchidism Testosterone enanthate Pituitary adenoma Hypothyroid hypoadrenal Testosterone enanthate 80 Essential hypertension Hydrocortisone 6 46 Pituitary adenoma Hypothyroid Testosterone enanthate Pituitary adenoma Hypothyroid hypoadrenal Testosterone enanthate 17 Hydrocortisone 8 42 Testicular failure Essential hypertension Testostero.1e enanthate 29 Hydrochlorothiazide Pindolol 41.1 ±4.2d a Testosterone (T) values reflect concentrations before any androgen replacement. To convert T to nmol/l, multiply by b IHH, isolated hypogonadotropic hypogonadism. Noninsulin-dependent diabetes mellitus. d Mean ± standard error of the mean. had hypopituitarism due to a pituitary adenoma, and one patient had post-traumatic testicular failure. Before entering the study, all patients had been receiving T enanthate for more than 2 years, and none reported erectile dysfunction or impaired libido. Their initial, pretreatment mean serum T concentration was 39 ± 8 ng/dl (Table 1), well below the lower limit of normal in our laboratory (250 ng/dl), reflecting low endogenous T secretion. Before entering the study, a medical history was obtained, and physical examination and routine laboratory studies were performed. IHH (patients nos. 1 to 4) and hypogonadism due to a pituitary adenoma (patients nos. 5 to 7) had been previously confirmed by a low serum T level ( <100 ng/dl) and inappropriately low serum gonadotropin levels. Primary gonadal failure, in patient no. 8, had been previously confirmed by a low serum T concentration and elevated serum gonadotropin levels. The study protocol was approved by the National Institutes of Health Institutional Review Board, and informed consent was obtained from each patient before starting the study. Study Design T enanthate was withheld for 8 weeks before receiving the microspheres in order to allow the serum T concentration to fall toward untreated, hypogonadallevels. At the end of the 8-week period of androgen withdrawal, immediately before injecting the T microspheres, blood was obtained for measurement of serum T, free T, dihydrotestosterone (DHT), testosterone-binding globulin (TeBG), and estradiol (E 2) levels. The T microspheres were administered through a 21-gauge needle by deep injection into the gluteal muscles. A total T dose of 630 mg was given to approximate the normal T production rate (5 to 10 mg/day) 1 for 12 weeks. The total injection volume, approximately 6 ml, was given in two separate 3-ml injections in order to minimize discomfort at the injection site. After administration of T microspheres, blood was obtained daily for 7 days and then weekly (on the seventh day of each week) for 14 weeks. At the end of the 14th week a physical examination and routine laboratory tests were repeated, and each patient received an intramuscular injection of T enanthate 200 mg to allow comparison of hormone concentrations achieved by the two different preparations. One week later, a final blood sample was obtained (week 15). Every week throughout the study, patients were asked about any changes in mood or sexual function. Testosterone Microspheres The T microspheres were formulated by Stolle Research and Development Corporation (Cincinnati, OH). The microsphere matrix consisted of poly(dl-lactide-co-glycolide) in an 85:15 molar ratio. The microspheres were loaded with 48% T (by 494 Burris et al. Testosterone microspheres Fertility and Sterility
3 RESULTS 1000 BOO. BOO ) 400 I I WEEKS Figure 1 Mean (±SEM) serum concentrations of testosterone (T) before (week 0) and after administration oft microspheres. The asterisk denotes values obtained 1 week after the administration oft enanthate. To convert to nmol/l,-multiply by weight) and were packaged in prefilled syringes, each containing 315 mg oft. The syringes were sterilized with gamma radiation and subsequently stored at room temperature until use. Just prior to injection, the microspheres were suspended in a diluent consisting of 2% carboxymethylcellulose and 1% polysorbate-20 in sterile water. Hormone Measurements Serum was promptly separated from blood samples and stored at -2o c until hormone analysis was performed. All hormone measurements for each patient were performed in a single assay to avoid interassay variation. T and DHT were separated by high-pressure liquid chromatography and subsequently measured by radioimmunoassay (RIA)Y The sensitivity of the assay is 1.0 ng/dl for both T and DHT. Serum E 2 and TeBG were measured by RIA using standard methods The sensitivities of the assays for E 2 and TeBG were 5 to 12 pg/ml and 0.10 JLg/dl, respectively. FreeT was measured by a solid-phase RIA (Diagnostic Products Corporation, Los Angeles, CA); the sensitivity of this assay is 0.06 ng/dl. Every sample was analyzed for both T and DHT, and alternate samples were analyzed for free T, E 2, and TeBG. Statistical Methods Data are shown as mean ± standard error of the mean (SEM). Comparisons between means were evaluated by Student's t-test or by analysis of variance (ANOV A) for multiple means. Statistical significance was defined as a P value less than Serum Hormone Concentrations T levels before and after the administration oft microspheres are shown in Figure 1. The mean total T concentration increased from 73 ± 32 to 641 ± 134 ng/dl on the first day after injection (P < 0.01), fell to a nadir of 173 ± 37 ng/dl during the third week, and subsequently rose again between weeks 6 and 11 (P < 0.05 compared with pre-injection concentration). A peak, meant concentration of 799 ± 198 ng/dl was observed at week 8. The mean free T concentrations (Fig. 2) paralleled the mean total T concentrations, with a peak of 2.2 ± 0.3 ng/dl during the first week (P < 0.01) and a prolonged rise between weeks 3 and 11 (P < 0.05); the peak value was 3.3 ± 0.7 at week 9. Mean DHT and E 2 concentrations (Fig. 2) followed a pattern similar to meant, but the postinjection concentrations were not significantly different from the preinjection concentrations. A slight, but not significant, fall in TeBG (Fig. 2) was noted at the time of the peak in T levels. As shown in Figures 1 and 2, the concentrations of total T, free T, and E 2 measured 1 week after T enanthate (week 15) were similar to values observed 6 to 11 weeks after the injection oft microspheres (P = NS). All DHT and TeBG concentrations observed after T microspheres were similar.. } 2 c ;e fnoot! w z if 3!!! "' ::? 2 "'!!! ill1 1!: iii 0.60 WEEKS '_j Figure 2 Mean (±SEM) serum concentrations of estradiol (E 2), dihydrotestosterone (DHT), free testosterone, and testosterone-binding globulin (TeBG) before (week 0) and after administration oft microspheres. The asterisk denotes values obtained 7 days after the administration oft enanthate (week 15). To convert to SI units, multiply values by the following constants: E 2, (pmol/l); free T, (nmol/l); DHT, (nmol/l). Burris et al. Testosterone microspheres 495
4 to those measured 1 week after T enanthate (P = NS). Clinical Course The injection oft microspheres was well-tolerated by the patients. They reported only transient, minimal discomfort at the time of injection, with one exception. Patient no. 8 experienced moderate pain during the injection; the microspheres he received had been suspended in diluent several hours before use, and clumping was noted in the syringe after injection. No other untoward effects were observed during the study. The efficiency of the microspheres injection, determined by measuring residual Tin the syringes after use, was 97.6 ± 0.05%. During the 8-week androgen withdrawal period, before the injection oft microspheres, all patients experienced symptoms of androgen deficiency, particularly describing a reduction in potency and libido. By the third week after the injection oft microspheres, seven of eight patients described the return of normal sexual function. Patient no. 8 did not experience an improvement in libido or potency after receiving the T microspheres and subsequently withdrew from the study after 5 weeks; his serum T concentration was 257 ng/dl at that time. In the seven remaining patients, normal sexual function was sustained during the 13 weeks after the injection oft microspheres (as ascertained by the sexual history). in the syringe; aggregation could account for his suboptimal clinical response. 14 The long-term efficacy and safety of sustained release hormone-loaded microspheres have been demonstrated in trials of progestin-loaded microspheres6'9 and luteinizing hormone-releasing hormone analog-loaded microspheres The biphasic rise in total and free T concentration that followed the injection of T microspheres was similar to the pharmacokinetics of progestin-loaded microspheres in initial trials.6 Subsequent reformulation of the progestin microspheres 8 9 resulted in nearly zero-order hormone release. Accordingly, we postulate that by varying the particle size, hormone content, polymer composition, and dose of sterilizing radiation, the T microspheres can be reformulated to provide near zero-order T release. 14 The results of our initial trial suggest that T microspheres may be a feasible alternative to current methods of long-term androgen replacement in hypogonadal men. By testing different microsphere preparations and by examining the pharmacokinetics of repeated doses of T microspheres, the suitability, for long-term use can be established. Acknowledgments. The authors acknowledge the invaluable nursing support of Ms. Nelly Rivera and Ms. Tannia Cartledge and editorial assistance of Ms. Kathy Shoobridge. They also thank Mrs. Elizabeth Higginbottom and Mr. Tushar Manek for technical assistance and acknowledge PARFR and the Stolle Corporation for supplying the testosterone microspheres. DISCUSSION This study demonstrates that sustained high T concentrations can be attained in hypogonadal men after the administration of T microspheres. Normal total T and free T concentrations were observed between the sixth and eleventh weeks after injection oft microspheres. The subjective, clinical response to the T microspheres paralleled the serum levels of total T and free T. Testosterone, free T, E 2, and DHT levels were comparable to those measured 1 week after a 200-mg dose of T enanthate. 2 4 Excessive hormone release from the T microspheres was not observed, neither was there clinical evidence of androgen- or estrogenmediated side effects such as stimulation of the prostate or breast enlargement. 1 Our experience with patient no. 8 indicates that the microspheres must be mixed in diluent immediately prior to use in order to avoid aggregation of the microspheres REFERENCES 1. Wilson JD, Griffin JE: The use and misuse of androgens. Metabolism 29:1278, Schulte-Beerbiihl M, Nieschlag E: Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril 33:201, Snyder PJ, Lawrence DA: Treatment of male hypogonadism with testosterone enanthate. J Clin Endocinol Metab 51:1335, Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS: Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 37:425, Beck LR, Pope VZ: Controlled-release delivery systems for hormones: a review of their properties and current therapeutic use. Drugs 27:528, Beck LR, Cowsar DR, Lewis DH, Cosgrove RJ, Riddle CT, Lowry SL, Epperly T: A new long-acting injectable microcapsule system for the administration of progesterone. Fertil Steril 31:545, Beck LR, Cowsar DR, Lewis DH, Gibson JW, Flowers CE: New long-acting injectable microcapsule contraceptive system. Am J Obstet Gynecol135:419, Burris et al. Testosterone microspheres Fertility and Sterility
5 8. Beck LR, Flowers CE, Pope VZ, Wilborn WH, Tice TR: Clinical evaluation of an improved injectable microcapsule contraceptive system. Am J Obstet Gynecol147:815, Beck LR, Ramos RA, Flowers CE, Lopez GZ, Lewis DH, Cowsar DR: Clinical evaluation of injectable biodegradable contraceptive system. Am J Obstet Gynecol140:799, Tice TR, Gilley RM, Flores RJ, Kirkpatrick, Asch RH: Three- and six-month controlled-release testosterone microcapsules (Abstract). Proceedings of the 12th International Symposium on Controlled Release of Bioactive Materials. Geneva, Switzerland, 1985, p Cochran RC, Ewing LL, Niswender GD: Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5a-dihydrotestosterone, 5a-androstane- 3a, 17/3-diol, 5a-androstane-3j3, 17/3-diol and 17/3-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia. Invest Urol19:142, Jiang N, Ryan RJ: Radioimmunoassay for estrogens: a preliminary communication. Mayo Clin Proc 44:461, Nisula BC, Dunn JF: Measurement of the testosterone binding parameter for both testosterone-estradiol binding globulin and albumin in individual serum samples. Steroids 34:771, Beck LR, Tice TR: Poly (lactic acid) and poly (lactic acidco-glycolic acid) contraceptive delivery systems. In Advances in Human Fertility and Reproductive Endocrinology, Edited by DR Mishell. New York, Raven Press, 1983, p Redding TW, Schally AV, Tice TR, Meyers WE: Long-acting delivery systems for pep tides: inhibition of rat prostate tumors by controlled release of [D-Trp 6 ]luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci 81:5845, Roger M, Chaussain JL, Berlier P, Bost M, Cnalorbe P, Colle M, Francois R, Garandeau P, Lahlou N, Morel Y, Schally A V: Long term treatment of male and female precocious puberty by periodic administration of D-Trp 6 -luteinizing hormone-releasing hormone microcapsules. J Clin Endocinol Metab 62:670, Sanders LM, Kent JS, McRae GI, Vickery BH, Tice TR, Lewis DH: Controlled release of a luteinizing hormone-releasing hormone analogue from poly(dl-lactide-co-glycolide) microspheres. J Pharm Sci 73:1294, 1984 Burris et al. Testosterone microspheres 497
Testosterone Topical/Buccal/Nasal
BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationNew long-acting androgens
World J Urol (2003) 21: 306 310 DOI 10.1007/s00345-003-0364-x TOPIC PAPER Louis J. Gooren New long-acting androgens Received: 16 September 2003 / Accepted: 17 September 2003 / Published online: 9 October
More informationReproductive DHT Analyte Information
Reproductive DHT Analyte Information - 1 - DHT Introduction Dihydrotestosterone (DHT) together with other important steroid hormones such as testosterone, androstenedione (ASD) and dehydroepiandrosterone
More informationIssues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationOriginal Research Declining testicular function in aging men
(2003) 15, Suppl 4, S3 S8 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Original Research 1 * 1 Wesley Woods Health Center, Atlanta, Georgia, USA Age-related
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES TESTOSTERON. Generic Brand HICL GCN Exception/Other ROUTE MISCELL.
Generic Brand HICL GCN Exception/Other ANDRODERM 01403 ROUTE MISCELL. ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO DEPO- 01400 ROUTE MISCELL. CYPIONATE TESTOSTERON E GCN 38586 DELATESTRYL 01401
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationDonald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone
Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent
Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred
More informationAffirming Care of the Transgender Patient
Mountain West AIDS Education and Training Center Affirming Care of the Transgender Patient Jessica Rongitsch, MD, FACP This presentation is intended for educational use only, and does not in any way constitute
More informationTREATMENT OPTIONS FOR MALE HYPOGONADISM
TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,
More informationFemale testosterone level chart
Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationFINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM
750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through
More informationMI Androgen Deficiency Hypogonadism
MI Androgen Deficiency Hypogonadism WADA TUE Expert Group John A Lombardo, MD October 2014, Columbus, Ohio USA Hypothalamic-Pituitary-Gonadal Axis / 2 Hypogonadism/Androgen Deficiency Clinical syndrome:
More informationThe physiology of normal androgen production in
Mayo Clin Proc, April 2004, Vol 79 (Supplement) Formulations and Use of Androgens S3 Supplement Article Formulations and Use of Androgens in Women MICHELINE C. CHU, MD, AND ROGERIO A. LOBO, MD The physiology
More informationAndrogenes and Antiandrogenes
Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More information1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride
1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride
More informationPolicy. covered: bilateral. alcohol or. Approve. 3. Palliative enanthate injection in. women for. 6 months if. can also sponsive tumor.
Injectablee Testosterone Products Prior Authorization Policy Number: 5.01.597 Origination: 07/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for injectable testosterone
More informationInsight into male menopause'
Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone
More informationMedical Policy Testosterone Therapy
Medical Policy Testosterone Therapy Subject: Testosterone Therapy Effective Date: April 2015 Overview: Testosterone cypionate, testosterone enanthate, testosterone undecanoate, and testosterone pellet
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Androgens and Anabolic Steroids Page 1 of 53 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior
More informationDrug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More informationAdverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function
Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Androgens and Anabolic Steroids Page 1 of 57 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior
More informationDr Tarza Jamal Pharmacology Lecture 2
Contraceptives and androgen hormone Contraceptives: Currently, interference with ovulation is the most common pharmacologic intervention for preventing pregnancy. Major classes of contraceptives 1. Combination
More informationJeremiah Murphy, MD Mercy Urology Clinic. October 21, 2017
Jeremiah Murphy, MD Mercy Urology Clinic October 21, 2017 Describe an appropriate strategy for the evaluation and diagnosis of male hypogonadism Endocrine Society Clinical Practice Guideline-2010 Review
More informationPRODUCT INFORMATION PROVIRON
PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5
More informationSeptember 17, FDA background documents for the discussion of two major issues in testosterone replacement therapy (TRT):
JOINT MEETING FOR BONE, REPRODUCTIVE AND UROLOGIC DRUGS ADVISORY COMMITTEE (BRUDAC) AND THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE (DSARM AC) September 17, 2014 FDA background documents for
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Implantable Hormone Pellets Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 6 Effective Date...
More informationAlthough women produce only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Mary Lake Polan, MD, PhD, MPH Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Chair Emeritus,
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationThe ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate
The ICL Insider February 2017 Volume 2, Issue 2 Lab Testing: Testosterone In This Issue Testosterone shashtilak@iclabs.ca Next Issue: Expected Release April 2017 The Debate Aging is accompanied by various
More informationANDROGENS PLAY AN essential role in the sexual
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5429 5434 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2004-0897 Intramuscular Testosterone
More informationNational Institute for Public Health and the Environment Annual CRL workshop 22 October Update on natural Hormone studies
2008 Annual CRL workshop 22 October 2008 Update on natural Hormone studies Natural hormone studies: update Possible approaches - C12/C13 ratio: can result in proof of abuse - Determination of intact esters
More informationDEPO-Testosterone Injection is available in two strengths, 100 mg/ml and 200 mg/ml testosterone cypionate.
Depo -Testosterone testosterone cypionate injection, USP CIII DESCRIPTION DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate
More informationMale Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2
Male Hormone Replacement Therapy Punita Dhindsa D.O PGY 2 Physiology of Testosterone & Causes of Hypogonadism in Males The use of testosterone therapy is very common in the US, with an estimated 2.3 million
More informationThe Science of. NUTRICULA Longevity Journal
32 December, 2011 The Science of 33 NUTRICULA Longevity Journal As men age, there is often a decline in libido and sexual function. This decline frequently interferes in intimacy within romantic relationships,
More informationPHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor
PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme
More informationAssociate Professor Geoff Braatvedt
Associate Professor Geoff Braatvedt Endocrinologist Diabetologist and Physician Green Lane and Auckland City Hospitals Auckland 14:00-14:55 WS #145: Approach to Low Testosterone Values 15:05-16:00 WS #157:
More informationFigure 2. RESULTS DATA ANALYSIS
ANDROGEN PARAMETERS IN HIRSUTE AND NORMAL FEMALE PATIENTS: IS THERE A ROLE FOR THE FREE ANDROGEN INDEX (FAI)? Castracane VD 1, Childress E 1, Tawwater B 1, Vankrieken L 2, El Shami AS 2 ( 1 Department
More informationNatural estrogens estradiol estrone estriol
Estrogens Natural estrogens estradiol estrone estriol Nonsteroidal synthetic Diethylstilbestrol Chlorotrianisene Methallenestril Steroidal synthetic Ethinyl estradiol Mestranol Quinestrol To decrease some
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationPros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery
Pros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery David T Zava, PhD ZRT laboratory A Guide to Steroid Hormone Testing in Different Body Fluids Following
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Current and Novel Therapeutic Options Module 4 2 Objectives Identify desirable characteristics of ideal testosterone formulations Review
More informationMedication Policy Manual
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Non-preferred, non-transdermal testosterone replacement therapy products (Android, Aveed, Androxy, Methitest,
More informationTreatment of androgen deficiency in the aging male
Treatment of androgen deficiency in the aging male The Practice Committee of the American Society for Reproductive Medicine Birmingham, Alabama Although guidelines for androgen replacement therapy for
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25
More informationRobert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration
-------------------- Robert Perlstein, M.D. Medical Officer Center for Drug Evaluation and Research U.S. Food & Drug Administration -------------------- Sentencing of Food and Drug Offenses Before the
More informationIcd-10 low levels of testosterone
Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases
More informationMens Health Post Puberty. Nayan Patel PharmD
Mens Health Post Puberty Nayan Patel PharmD Definition of Androgen Deficiency * Consistently low testosterone * Associated signs/symptoms * Evidence based review of literature * Data is weak at best Definition
More informationMALE HORMONE THERAPY OPTIONS
MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women s logo is placed throughout
More informationTransgender 201: Case Discussion Group
Transgender 201: Case Discussion Group Melissa Davis, MD Maria Barnett, DO October 19, 2017 Maria Barnett, DO, Date Welcome! Disclosures Introductions Discussion The total time of this workshop will depend
More information4.2 Posology, method and duration of administration
The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it in May 2011. 1. NAME OF MEDICINAL PRODUCT Testoviron Depot Oily solution for injection
More informationClinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일
Clinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일 Development of 5ARI Discovery of 5AR type I and type II Pharmacodynamic and pharmacokinetic
More informationPRESCRIBING INFORMATION
PRESCRIBING INFORMATION C DELATESTRYL* testosterone enanthate Solution for Injection, 200 mg/ml Androgens Valeant Canada LP 2150 Blvd. St-Elzear West Laval, Quebec H7L 4A8 Date of Revision: August 19,
More informationHypogonadism and Testosterone Replacement Therapy
Testosterone Replacement Therapy Hypogonadism and Testosterone Replacement Therapy a report by Adrian S Dobs, MD, MHS and Anjana Myneni, MD Professor of Medicine and Oncology, Department of Medicine, Johns
More informationLong-term experience with testosterone replacement through scrotal skin
CHAPTER 13 1 Long-term experience with testosterone replacement through scrotal skin Linda E. Atkinson, Yu-Lin Chang, and Peter J. Snyder Contents 13.1 13.1.1 13.1.2 13.2 13.2.1 13.2.2 13.2.2.1 13.2.2.2
More informationIcd 10 hormone replacement therapy male
Icd 10 hormone replacement therapy male 2018 ICD - 10 code for Hormone replacement therapy is Z79.890. Lookup the complete ICD 10 Code details for Z79.890. The ICD - 10 system requires that. TEENren who
More informationXYOSTED (testosterone enanthate) injection, for subcutaneous use CIII Initial US approval: 1953 IMPORTANT SAFETY INFORMATION
ANTARES PHARMA ANNOUNCES THE COMMERCIAL AVAILABILITY OF XYOSTED (TESTOSTERONE ENANTHATE) INJECTION A NEW TREATMENT FOR ADULT MEN DIAGNOSED WITH TESTOSTERONE DEFICIENCY XYOSTED - A Novel Subcutaneous Testosterone
More informationPackage Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)
Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains
More informationPRODUCT MONOGRAPH DEPO-TESTOSTERONE. testosterone cypionate injection. 100 mg/ml sterile solution USP. Androgens
PRODUCT MONOGRAPH DEPO-TESTOSTERONE testosterone cypionate injection 100 mg/ml sterile solution USP Androgens Pfizer Canada Inc. 17, 300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Revision:
More informationGynaecomastia. Benign breast conditions information provided by Breast Cancer Care
Gynaecomastia This booklet tells you about gynaecomastia. It explains what gynaecomastia is, what causes it, how it s diagnosed and what will happen if it needs to be treated or followed up. Benign breast
More informationAndroGel. (testosterone gel) 1% H 3 C
1 AndroGel (testosterone gel) 1% 500122/500127 Rev Dec 2004 DESCRIPTION AndroGel (testosterone gel) is a clear, colorless hydroalcoholic gel containing 1% testosterone. AndroGel provides continuous transdermal
More informationMonth/Year of Review: September 2013 Date of Last Review: December 2009
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2013 Oregon State University. All Rights
More informationTESTOFEN. Anabolic & Androgenic Activity GENCOR PACIFIC, INC. Fenugreek Extract standardized for FENUSIDE TM. Copyright 2005 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920E. Orangethorpe Avenue, Suite B, Anaheim, CA. 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com manu@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationInappropriate Testosterone Billings
Inappropriate Testosterone Billings Carla Patrick-Fagan March 30, 2015 Truven Health Analytics Inc. All Rights Reserved. 1 Agenda Proposed in the 2015 analytic plan Steroid prescriptions Code of Federal
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationTESTIM (testosterone gel) for topical use, CIII Initial U.S. Approval: 1953
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TESTIM safely and effectively. See full prescribing information for TESTIM. TESTIM (testosterone
More informationDUPROST Capsules (Dutasteride)
Published on: 10 Jul 2014 DUPROST Capsules (Dutasteride) Composition Each soft gelatin capsule contains: Dutasteride... 0.5 mg Dosage Form Capsule Pharmacology Pharmacodynamics Mechanism of Action Dutasteride
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More informationSUMMARY and OBJECTIVES. LOW T- I m half the man I used to be. Prevalence of Low-T. Definition of Hypogonadism 9/19/ Million men in the US
SUMMARY and OBJECTIVES LOW T- I m half the man I used to be A discussion of male hypogonadism David Doriguzzi, PA-C Valley Endocrine & Diabetes Consultants Definition Prevalence Causes Signs & Symptoms
More informationPRODUCT INFORMATION. Testosterone Phenylpropionate: Testosterone Phenylpropionate is 3-oxoandrost-4-en-17β-yl
PRODUCT INFORMATION SUSTANON '250' NAME OF THE MEDICINE Sustanon '250' ('250' mg/ml for injection): testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone decanoate.
More informationChapter 5. General discussion
Chapter 5. General discussion 127 Chapter 5 In 2003, two review papers concluded that endogenous androgens do not show any consistent association with cardiovascular disease (CVD) risk 1,2. Apparently,
More informationMale pattern baldness is the most common type of balding among males. It affects roughly, 50% of men by the age of 50,
Dihydrotestosterone (DHT) Male pattern baldness is the most common type of balding among males. It affects roughly, 30% of men by the age of 30, 50% of men by the age of 50, 57% of men by the age of 60.
More informationSummary. Introduction. Dow Stough, MD
Original Contribution Blackwell Publishing ORIGINAL Inc CONTRIBUTION Dutasteride improves male pattern hair loss in a randomized study in identical twins Dow Stough, MD The Dermatology Clinic, Hot Springs,
More informationClinical Policy: Testosterone Reference Number: AZ.CP.PHAR.02 Effective Date: Last Review Date: Line of Business: Arizona Medicaid
Clinical Policy: Reference Number: AZ.CP.PHAR.02 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for
More informationSkin metabolism of steroid hormones as endogenous compounds?
Skin metabolism of steroid hormones as endogenous compounds? Van Luu-The Department of Molecular Medicine Laval University Québec, Canada This work has been supported by L Oréal Research Steroid hormones
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. FINASTERIDE 1 MG FILM-COATED TABLETS (finasteride)
PACKAGE LEAFLET: INFORMATION FOR THE USER FINASTERIDE 1 MG FILM-COATED TABLETS (finasteride) Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationAndrogen deficiency in the aging male
Androgen deficiency in the aging male Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology The American Society for Reproductive
More informationThe Testosterone Quandary. Beth Crowder, PhD, APRN
The Testosterone Quandary Beth Crowder, PhD, APRN Objectives Define testosterone, the hypothalamic-pituitary-gonadotrophic axis, and normal blood levels List functions of testosterone and symptoms of low
More informationPharmacokinetics, safety and tolerability of three dosage regimens of buccal adhesive testosterone tablets in healthy men suppressed with leuprorelin
813 Pharmacokinetics, safety and tolerability of three dosage regimens of buccal adhesive testosterone tablets in healthy men suppressed with leuprorelin K J Baisley, M J Boyce, S Bukofzer 1, R Pradhan
More informationsocial impairment. The following exclusion criteria applied: age under 18 years; weight under 45 kg or over 80 kg;
Postgrad Med J (1991) 67, 450-454 The Fellowship of Postgraduate Medicine, 1991 Low dose danazol in the treatment of the premenstrual syndrome Miriam Deeny, Robert Hawthorn and D. McKay Hart Division ofobstetrics
More informationFINCAR Tablets (Finasteride)
Published on: 10 Jul 2014 FINCAR Tablets (Finasteride) Composition FINCAR Tablets Each film-coated tablet contains: Finasteride USP - 5 mg Dosage Form Tablet Pharmacology Pharmacodynamics Mechanism of
More informationAnalog-Based Free Testosterone Test Results Linked to Total Testosterone Concentrations, Not Free Testosterone Concentrations
Papers in Press. Published January 2, 28 as doi:1.1373/clinchem.27.9487 The latest version is at http://www.clinchem.org/cgi/doi/1.1373/clinchem.27.9487 Clinical Chemistry 54:3 (28) Endocrinology and Metabolism
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationAll About T Testosterone for FTMs. Presented by John Otto, MLIS
All About T Testosterone for FTMs Presented by John Otto, MLIS Who? Anyone thinking about transitioning Those who have transitioned, but want to know more Empowerment from self-managing transition Allies
More informationTESTOSTERONE gel, for topical use, CIII Initial U.S. Approval: 1953
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TESTOSTERONE gel safely and effectively. See full prescribing information for TESTOSTERONE gel. TESTOSTERONE
More informationMale hypogonadism is a clinical syndrome that
Journal of Andrology, Vol. 33, No. 4, July/August 2012 Copyright E American Society of Andrology A Novel Testosterone 2% Gel for the Treatment of Hypogonadal Males ADRIAN S. DOBS,* JOHN MCGETTIGAN,{ PAUL
More informationA mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men
European Journal of Endocrinology (2004) 151 241 249 ISSN 0804-4643 EXPERIMENTAL STUDY A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men Paul
More informationPharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men
European Journal of Endocrinology (2002) 146 673 679 ISSN 0804-4643 CLINICAL STUDY Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men C Rolf, S Kemper, G Lemmnitz
More informationUpdates on Anti-doping and TUE Management in Paralympic Sport
International Paralympic Committee Updates on Anti-doping and TUE Management in Paralympic Sport Matthew Fedoruk, Ph.D. March 15, 2018 PyeongChang 2018 IPC Medical / Sports Science Committee Workshops
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases
More information